Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma.
Thirty-one patients with disseminated malignant melanoma were treated with a combination chemotherapy of bleomycin, dacarbazine and vindesine. Five complete responses, and five partial remissions occurred. One patient survived for over 2 years without evidence of disease. This combination of drugs may give better results, as far as complete recovery and long-term survival are concerned, than single-agent therapy with dacarbazine.
Mulder
N H
NH
Department of Internal Medicine, University Hospital Groningen, The Netherlands.
Sleijfer
D T
DT
de Vries
E G
EG
Schraffordt Koops
H
H
Samson
M J
MJ
Willemse
P H
PH
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D014751:Vindesine / Q000008:administration & dosage
D001761:Bleomycin; D003606:Dacarbazine; D014751:Vindesine